1-16 of 16
Maria Verdugo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

Clinical Trials & Observations
Andrew W. Roberts, Shuo Ma, Thomas J. Kipps, Steven E. Coutre, Matthew S. Davids, Barbara Eichhorst, Michael Hallek, John C. Byrd, Kathryn Humphrey, Lang Zhou, Brenda Chyla, Jacqueline Nielsen, Jalaja Potluri, Su Young Kim, Maria Verdugo, Stephan Stilgenbauer, William G. Wierda, John F. Seymour
Journal: Blood
Blood (2019) 134 (2): 111–122.
https://doi.org/10.1182/blood.2018882555
Published: 2019
Includes: Supplemental data
Journal Articles

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

Clinical Trials & Observations
Ian W. Flinn, John G. Gribben, Martin J. S. Dyer, William Wierda, Michael B. Maris, Richard R. Furman, Peter Hillmen, Kerry A. Rogers, Swaminathan Padmanabhan Iyer, Anne Quillet-Mary, Loic Ysebaert, Harriet S. Walter, Maria Verdugo, Christian Klein, Huang Huang, Yanwen Jiang, Gerard Lozanski, Daniela Soriano Pignataro, Kathryn Humphrey, Mehrdad Mobasher, Thomas J. Kipps
Journal: Blood
Blood (2019) 133 (26): 2765–2775.
https://doi.org/10.1182/blood-2019-01-896290
Published: 2019
Includes: Supplemental data
Journal Articles

Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

Clinical Trials & Observations
Steven Coutre, Michael Choi, Richard R. Furman, Herbert Eradat, Leonard Heffner, Jeffrey A. Jones, Brenda Chyla, Lang Zhou, Suresh Agarwal, Tina Waskiewicz, Maria Verdugo, Rod A. Humerickhouse, Jalaja Potluri, William G. Wierda, Matthew S. Davids
Journal: Blood
Blood (2018) 131 (15): 1704–1711.
https://doi.org/10.1182/blood-2017-06-788133
Published: 2018
Includes: Supplemental data
Journal Articles

Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor Therapy

Anthony R. Mato, MD, William G Wierda, MD PhD, Matthew S. Davids, MD, Bruce D. Cheson, MD, Steven Coutre, MD, Michael Choi, MD, Richard R. Furman, Leonard Heffner, MD, Paul M. Barr, MD, Herbert Eradat, Lang Zhou, Maria Verdugo, MD, Jalaja Potluri, Jeffrey Jones, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 834.
https://doi.org/10.1182/blood.V130.Suppl_1.834.834
Published: 2017
Journal Articles

Venetoclax (VEN) Is Active in Chronic Lymphocytic Leukemia (CLL) Relapsed or Refractory to More Than One B-Cell Receptor Pathway Inhibitor (BCRi)

William G Wierda, MD PhD, Matthew S. Davids, MD, Richard R. Furman, Bruce D. Cheson, MD, Paul M. Barr, MD, Herbert Eradat, Leonard Heffner, MD, Jeffrey Jones, MD, Lang Zhou, Maria Verdugo, MD, Rod A. Humerickhouse, Jalaja Potluri, Michael Choi, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3025.
https://doi.org/10.1182/blood.V130.Suppl_1.3025.3025
Published: 2017
Journal Articles

Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, MD, Cristina J. Gasparetto, MD, Joseph Mikhael, MD, Philippe Moreau, MDPhD, Cyrille Touzeau, MD PhD, Ravi Vij, MDMBA, Thierry Facon, MD, Brigitte Pegourie, MD, Lofti Benboubker, MD, Lawrence H. Boise, PhD, Stefanie Alzate, MSc, Martin Dunbar, DRPH, MS, Jia Jia, PhD MBA, Kevin J. Freise, PhD, Maria Verdugo, MD, Jeremy Ross, PhD MBA, Paulo Maciag, MD PhD, Shaji K Kumar, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3131.
https://doi.org/10.1182/blood.V130.Suppl_1.3131.3131
Published: 2017
Journal Articles

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

Clinical Trials & Observations
Shaji Kumar, Jonathan L. Kaufman, Cristina Gasparetto, Joseph Mikhael, Ravi Vij, Brigitte Pegourie, Lofti Benboubker, Thierry Facon, Martine Amiot, Philippe Moreau, Elizabeth A. Punnoose, Stefanie Alzate, Martin Dunbar, Tu Xu, Suresh K. Agarwal, Sari Heitner Enschede, Joel D. Leverson, Jeremy A. Ross, Paulo C. Maciag, Maria Verdugo, Cyrille Touzeau
Journal: Blood
Blood (2017) 130 (22): 2401–2409.
https://doi.org/10.1182/blood-2017-06-788786
Published: 2017
Includes: Supplemental data
Journal Articles

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM

Clinical Trials & Observations
Philippe Moreau, Asher Chanan-Khan, Andrew W. Roberts, Amit B. Agarwal, Thierry Facon, Shaji Kumar, Cyrille Touzeau, Elizabeth A. Punnoose, Jaclyn Cordero, Wijith Munasinghe, Jia Jia, Ahmed Hamed Salem, Kevin J. Freise, Joel D. Leverson, Sari Heitner Enschede, Jeremy A. Ross, Paulo C. Maciag, Maria Verdugo, Simon J. Harrison
Journal: Blood
Blood (2017) 130 (22): 2392–2400.
https://doi.org/10.1182/blood-2017-06-788323
Published: 2017
Includes: Supplemental data
Journal Articles

Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia

John F Seymour, Matthew S. Davids, Andrew W. Roberts, Michael Hallek, William G. Wierda, MD PhD, Peter Hillmen, John F. Gerecitano, Elisa Cerri, Jalaja Potluri, Su Young Kim, Todd Busman, Maria Verdugo, Rod A. Humerickhouse, MD, Andrea Best, Monali Desai, Stephan Stilgenbauer
Journal: Blood
Blood (2016) 128 (22): 4395.
https://doi.org/10.1182/blood.V128.22.4395.4395
Published: 2016
Journal Articles

Detailed Safety Analysis of Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Danielle M. Brander, MD, Michael Y. Choi, MD, Andrew W. Roberts, Shuo Ma, L. Leanne Lash, Maria Verdugo, Ming Zhu, Su Young Kim, John F Seymour
Journal: Blood
Blood (2016) 128 (22): 2033.
https://doi.org/10.1182/blood.V128.22.2033.2033
Published: 2016
Journal Articles

Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study

Shaji Kumar, MD, Ravi Vij, MD, Jonathan L. Kaufman, MD, Joseph Mikhael, MD, Thierry Facon, MD, Brigitte Pegourie, MD, Lofti Benboubker, Cristina Gasparetto, MD, Martine Amiot, Philippe Moreau, Stefanie Alzate, Jeremy Ross, Martin Dunbar, Tu Xu, Suresh Agarwal, Joel Leverson, Paulo Maciag, Maria Verdugo, Cyrille Touzeau
Journal: Blood
Blood (2016) 128 (22): 488.
https://doi.org/10.1182/blood.V128.22.488.488
Published: 2016
Journal Articles

Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma

Philippe Moreau, Asher A. Chanan-Khan, MD, Andrew W. Roberts, Amit B. Agarwal, Thierry Facon, MD, Shaji Kumar, MD, Cyrille Touzeau, Jaclyn Cordero, Jeremy Ross, Wijith Munasinghe, Jia Jia, Ahmed H. Salem, Joel Leverson, Paulo Maciag, Maria Verdugo, Simon J. Harrison
Journal: Blood
Blood (2016) 128 (22): 975.
https://doi.org/10.1182/blood.V128.22.975.975
Published: 2016
Journal Articles

Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib

Jeffrey Jones, Michael Y. Choi, MD, Anthony R. Mato, Richard R. Furman, Matthew S. Davids, Leonard T. Heffner, MD, Bruce D. Cheson, Nicole Lamanna, MD, Paul M. Barr, Herbert Eradat, Ahmad Halwani, Brenda Chyla, Ming Zhu, Maria Verdugo, Rod A. Humerickhouse, MD, Jalaja Potluri, William G. Wierda, MD PhD, Steven E. Coutre, MD
Journal: Blood
Blood (2016) 128 (22): 637.
https://doi.org/10.1182/blood.V128.22.637.637
Published: 2016
Journal Articles

Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Andrew W. Roberts, John F Seymour, Barbara Eichhorst, MD, Stephan Stilgenbauer, Michael Y. Choi, MD, Matthew S. Davids, John F. Gerecitano, Relja Popovic, Brenda Chyla, Ming Zhu, Maria Verdugo, Jalaja Potluri, Leanne Lash, Su Young Kim, Michael Hallek
Journal: Blood
Blood (2016) 128 (22): 3230.
https://doi.org/10.1182/blood.V128.22.3230.3230
Published: 2016
Journal Articles

Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study

Stephan Stilgenbauer, MD PhD, Barbara F. Eichhorst, MD, Johannes Schetelig, MD, M.Sc, Steven Coutre, MD, John F. Seymour, MBBS, PhD, Talha Munir, MBBS, MRCP, FRCPath, Soham D. Puvvada, MD, Clemens-Martin Wendtner, MD, Andrew W. Roberts, MBBS, PhD, Wojciech Jurczak, MD, PhD, Stephen Mulligan, MBBS, PhD, FRACP, FRCPA, Sebastian Boettcher, MD, Mehrdad Mobasher, MD, Ming Zhu, PhD, Brenda Chyla, PhD, Maria Verdugo, MD, Sari Heitner Enschede, MD, Elisa Cerri, MD, Rod A. Humerickhouse, MD, PhD, Gary Gordon, MD, PhD, Michael Hallek, MD, William Wierda, MD, PhD
Journal: Blood
Blood (2015) 126 (23): LBA-6.
https://doi.org/10.1182/blood.V126.23.LBA-6.LBA-6
Published: 2015
Journal Articles

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results

Philippe Moreau, MD PhD, Asher Chanan-Khan, MD, Andrew W. Roberts, MBBS, PhD, Amit B. Agarwal, MDPhD, Thierry Facon, Shaji Kumar, MD, Cyrille Touzeau, MD, David Darden, MS, Lura Morris, BA, Jeremy Ross, PhD, Ahmed H Salem, PhD, Wijith Munasinghe, PhD, Ming Zhu, PhD, Joel Leverson, PhD, Paulo Maciag, MD, Sari Heitner Enschede, MD, Maria Verdugo, MD, Rod A. Humerickhouse, MD PhD, Simon Harrison, MD
Journal: Blood
Blood (2015) 126 (23): 3038.
https://doi.org/10.1182/blood.V126.23.3038.3038
Published: 2015